Safal Lifescience Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
- Paid Up Capital ₹ 4.00 Cr
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 9.50 Cr
- Revenue Growth 87.78%
- Profit Growth 8.66%
- Ebitda -58.26%
- Net Worth -48.23%
- Total Assets 7.53%
About Safal Lifescience
Safal Lifescience Private Limited (SLPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 May 2016 (Eight years and nine months 7 days old ). Its registered office is in Mahesana, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 4.00 Cr.
The company has closed loans amounting to ₹9.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Navinbhai Mehta and Jignesh Mehta serve as directors at the Company.
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230GJ2016PTC092075
- Company No.
092075
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 May 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Safal Lifescience?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Navinbhai Mehta  | Director | 02-Apr-2019 | Current |
| Jignesh Mehta | Director | 02-Apr-2019 | Current |
Financial Performance of Safal Lifescience.
Safal Lifescience Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 87.78% increase. The company also saw a slight improvement in profitability, with a 8.66% increase in profit. The company's net worth observed a substantial decline by a decrease of 48.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Safal Lifescience?
In 2021, Safal Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Newtronic Lifecare Equipment Private LimitedNavinbhai Mehta and Jignesh Mehta are mutual person
Charges (Loans)
₹0
₹9.50 Cr
Charges Breakdown by Lending Institutions
- State Bank Of India : 9.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Apr 2018 | State Bank Of India | ₹9.50 Cr | Satisfied |
How Many Employees Work at Safal Lifescience?
Safal Lifescience has a workforce of 50 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Safal Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Safal Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
